(ARCT) |
| 0 (0%) 06-05 08:01 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 9.58 |
| Resistance 1: | 8.47 |
| Pivot price: | 7.44 |
| Support 1: | 6.67 |
| Support 2: | 5.55 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -85480000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -38.430 |
| Profit Margin (%) | -143.80 |
| Operating Margin (%) | -1.00 |
| Return on Assets (ttm) | 403.7 |
| Return on Equity (ttm) | -19.1 |
Company news
Fri, 05 Jun 2026
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies - Yahoo Finance
Thu, 04 Jun 2026
ARCT: Promising phase II data in CF and liver disease, plus global COVID vaccine approval and new leadership - TradingView
Fri, 29 May 2026
(ARCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Thu, 07 May 2026
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Thu, 07 May 2026
ARK/ Cathie Wood report 2.95M shares in Arcturus (ARCT) - Stock Titan
Thu, 16 Apr 2026
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: Navigating a 170% Potential Upside with Innovative Biotechnology - DirectorsTalk Interviews
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
